lengsin, lens protein with glutamine synthetase domainGenealiases: GLULD1 · LGS
Q-omics provides the consensus-scored LGSN profile across patient tissues and cancer cell-line models. LGSN expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LGSN is differentially expressed in 10, with the highest sampling consensus in KIRP. Additionally, LGSN protein abundance shows 14,761 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight KIRC, KIRP, and LUAD as cancer lineages where LGSN shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LGSN — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LGSN survival associations across molecular data types. LGSN RNA expression shows survival associations in the most cancer types (22), followed by mutation status (6) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LGSN RNA expression–survival associations across cancer types. High LGSN expression shows unfavorable associations in LGG, COAD, ACC and DLBC, but favorable associations in KIRC and LIHC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for LGSN RNA expression.
This table summarizes LGSN tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRP for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for LGSN. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LGSN shows lower tumor expression in KIRP, KICH, KIRC, LIHC and CHOL and higher tumor expression in LUAD. The KIRP box plot shows higher LGSN RNA expression in normal versus tumor tissue (log2 FC = −1.088, t-test p < 0.001).
This table shows molecular features associated with LGSN in patient tissues and cancer cell lines. In patient samples, LGSN shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, LGSN RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and LIVER.
